MED MEDIFAST INC
Miscellaneous Food Preparations & Kindred Products · NYSE · SEC CIK 910329 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-30.3%
TTM net income YoY-16,572.6%
TTM EPS YoY-18,600.0%
Revenue 3-yr CAGR-37.4%
Net income 3-yr CAGR—
Margins
Gross margin69.2%
Operating margin-11.6%
Net margin-13.6%
FCF margin-1.3%
EBITDA margin-7.4%
Returns
ROE-20.7%
ROA-16.1%
ROIC (approx.)-23.2%
Asset turnover1.18x
Leverage & solvency
Liabilities / assets24.8%
Debt / equity0.00x
Current ratio4.82x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.00x
Accruals ratio-16.1%
Payout ratio—
Capex / revenue1.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $385.79M | $602.46M | $1.07B | $1.60B | $1.53B |
| Cost of revenue | $110.60M | $157.84M | $296.20M | $458.16M | $398.49M |
| Gross profit | $275.19M | $444.62M | $775.85M | $1.14B | $1.13B |
| R&D expense | $4.30M | $4.60M | $4.60M | $4.50M | $4.40M |
| SG&A expense | $289.40M | $441.75M | $649.45M | $955.61M | $911.36M |
| Operating income | -$14.21M | $2.88M | $126.40M | $184.81M | $216.24M |
| Pretax income | -$5.64M | $3.79M | $128.80M | $184.06M | $216.13M |
| Income tax | $13.03M | $1.70M | $29.38M | $40.49M | $52.10M |
| Net income | -$18.67M | $2.09M | $99.42M | $143.57M | $164.03M |
| EBITDA | $29,000 | $15.59M | $139.51M | $195.79M | $223.05M |
| EPS (basic) | -1.70 | 0.19 | 9.13 | 12.82 | 14.01 |
| EPS (diluted) | -1.70 | 0.19 | 9.10 | 12.73 | 13.89 |
| Dividends declared per share | 0.00 | 0.00 | 4.95 | 6.56 | 5.68 |
| Weighted avg. shares (diluted) | 10.98M | 10.96M | 10.92M | 11.28M | 11.81M |
| Balance sheet | |||||
| Cash & equivalents | $89.30M | $90.93M | $94.44M | $87.69M | $104.18M |
| Short-term investments | $77.97M | $71.42M | $55.60M | $0 | $5.36M |
| Inventory | $20.23M | $42.42M | $54.59M | $118.86M | $180.04M |
| Current assets | $201.68M | $214.40M | $224.03M | $222.78M | $306.87M |
| PP&E, net | $31.23M | $37.53M | $51.47M | $57.19M | $56.13M |
| Total assets | $247.97M | $284.21M | $309.91M | $316.21M | $398.33M |
| Current liabilities | $42.96M | $64.16M | $92.30M | $140.89M | $169.83M |
| Total liabilities | $49.05M | $74.10M | $108.43M | $161.17M | $195.85M |
| Shareholders' equity | $198.92M | $210.11M | $201.48M | $155.04M | $202.47M |
| Shares outstanding | 10.99M | 10.94M | 10.90M | 10.87M | 11.59M |
| Cash flow statement | |||||
| Operating cash flow | $6.86M | $24.48M | $147.66M | $194.57M | $94.55M |
| Capital expenditure | $5.61M | $7.45M | $6.48M | $16.68M | $34.21M |
| Free cash flow | $1.25M | $17.02M | $141.17M | $177.89M | $60.34M |
| Investing cash flow | -$7.93M | -$26.52M | -$61.05M | -$11.41M | -$29.06M |
| Financing cash flow | -$564,000 | -$1.51M | -$79.79M | -$199.58M | -$125.13M |
| Depreciation & amortization | $14.24M | $12.71M | $13.11M | $10.98M | $6.81M |
| Stock-based compensation | $7.64M | $7.36M | $8.19M | $11.05M | $9.90M |
| Dividends paid | $195,000 | $715,000 | $73.02M | $71.62M | $63.86M |
| Share buybacks | $0 | $0 | $3.60M | $126.44M | $56.00M |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.